Scottish Medicines Consortium Accepts Chemotherapy-free Combination Treatment VENCLYXTO[®]▼(Venetoclax) Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia
· Patients in Scotland with previously untreated chronic lymphocytic leukaemia (CLL) now have access to a chemotherapy-free, 12-month, fixed-duration treatment option.[1] · Scottish Medicines Consortium (SMC) acceptance is based on data from the Phase III CLL14 trial, which showed patients receiving 1 year of treatment with venetoclax plus obinutuzumab had superior progression-free survival compared with those receiving a commonly used chemo-immunotherapy regimen of obinutuzumab and chlorambucil, with patients sustaining that benefit after stopping treatment.[2,3] · CLL is the most